Pharma join together to achieve new standards in digital and patient innovation for clinical transformation

Reuters Events 17 - 19 May 2022, Virtual.
On May 17th , 500+ of pharma's clinical innovation will come together for the home of clinical collaboration, Reuters Events: Pharma Clinical 2022, to set new standards in digital and patient innovation for clinical transformation.

The catalyst for this has been the accelerated technological adoption in clinical trials, but a general feeling still that enough isn't being done for patients, failing to develop co-created, data-driven, standardised and accountable trial design.

Senior leaders from Sanofi, Pfizer, Bayer, FDA, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Roche, Novartis and more are collaborating on May 17 th , with one mission in mind: it's time to develop a better system. "We must establish new industry-wide benchmarks, leverage digital technology, and ensure permanent cultural change toward patient- centric trials. If we don't act immediately, we risk losing patient trust." Said Usmaan Khan, Global Project Director and leader for Reuters Events: Pharma Clinical 2022.

The community is growing every day so don't miss out on the opportunity to be part of this movement- this event is free for pharma and biotech executives, patient advocates and patient associations! Secure your pass today here.

About Reuters Events: Pharma Clinical 2022, May 17-19th

Reuters Events: Pharma Clinical is proud to host a one-of-a-kind lineup, with more than 40 world-class and professional speakers. Among the speakers are:
  • Jijo James, CMO, Medical Devises, Johnson & Johnson
  • Lionel Bascles, SVP, Global Head of Clinical Sciences & Operations, Sanofi
  • Craig Lipset, Advisor and founder, Clinical Innovations Partners
  • Loredana Regep, VP Medical and Regulatory Affairs, Roche
  • Najat Khan, Chief Data Science Officer, Global Head, Janssen R&D Strategy and Operations, Johnson & Johnson
  • Dietmar Berger, CMO, Global Head of Development, Sanofi
  • Tracy Vanderslice, VP & Head, Pharma Global Clinical Operations, GSK
  • Venkat Sethuraman, SVP Global Biometrics and Data Science, Bristol-Myers Squibb

Click here to discover the full speaker line-up now!

Why should you attend?

On last year's event, Mo Ali, VP Digital Analytics and Performance said: "Clinical 2021 allows for open discussions around how we can do this, by sharing experiences and learnings, we expand on the art of the possible from what once several years ago may have been viewed as impossible"

Clinical 2022 builds on this with our insight-driven agenda co-created with industry leaders to guarantee you acquire practical knowledge that will help you succeed. With 40+ speakers, you'll access critical sessions related to:

  • Benchmark industry-wide clinical innovation: Align standards across stakeholders, establish benchmarks, maintain accountability, and set industry-wide goals to improve patient experience and trial performance
  • Co-creation or no creation: Create shared missions, education programmes, and centre digital advances around patients to create trial designs that work in the real world
  • Optimise your digital and data strategies for novel endpoints: Develop trial flexibility, design efficiency, and unique RWE endpoints through standardised and tested innovations
  • Data collaboration: Ensure smooth interoperable data transmissions across the company's digital innovation and health networks for streamlined trials
  • Evolve decentralised trials: Allow decentralised trials to thrive by providing ongoing trial breakthroughs that are backed by regulators and prioritise the patient.

Interested in sponsoring or speaking at Clinical 2022? Fill out the form here.

For further information and to register, please visit Pharma Clinical 2022

About Reuters Events

Our mission is to make pharma more open and valued.

More open so that the strongest ideas and insights are brought to the fore in a transparent, trustworthy manner. More valued by having an authentic approach to building products and services that matter to patients.

To do this, Reuters Events provides a hub for senior-level pharma executives, patient groups and other health stakeholders to exchange ideas and observe shifting trends and practices. We provide commentary, events, reports, and other expert-driven content. One of our biggest strengths is to be able to gather advice, examples and understanding on the best industry work, articulate this across multiple channels, and create a mass movement to help us all improve. This is how we will serve patients better.

We actively respond to the aims and interests of our audience, so please get in touch if you think we can do more.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...